An Act To Ensure the Safety of Compounded Drugs
Maine Legislature, Session 126, LD 1315
Committee: Labor, Commerce, Research and Economic Development
Sponsors: TREAT, CRAVEN, FARNSWORTH, GATTINE, GRAHAM, PRINGLE, SANBORN
Amends: 32 MRSA §13702-A, 32 MRSA §13712, 32 MRSA §13713, 32 MRSA §13715-B, 32 MRSA §13721, 32 MRSA §13722, 32 MRSA §13723, 32 MRSA §13724, 32 MRSA §13735, 32 MRSA §13751, 32 MRSA §13752, 32 MRSA §13754, 22 MRSA §2149-B, 22 MRSA §7808, 22 MRSA §8624, 22-A MRSA §206, 32 MRSA §2108-B, 32 MRSA §2581, 32 MRSA §2600-C, 32 MRSA §3269, 32 MRSA §3300-D

Legislative Document 
No. 1315 
H.P. 934 
House of Representatives, April 2, 2013 
An Act To Ensure the Safety of Compounded Drugs 
Reference to the Committee on Labor, Commerce, Research and Economic Development 
suggested and ordered printed. 
MILLICENT M. MacFARLAND 
Clerk 
Presented by Representative TREAT of Hallowell. 
Cosponsored by Senator CRAVEN of Androscoggin and 
Representatives: FARNSWORTH of Portland, GATTINE of Westbrook, GRAHAM of North 
Yarmouth, PRINGLE of Windham, SANBORN of Gorham. 
Be it enacted by the People of the State of Maine as follows: 
PART A 
Sec. A-1.  32 MRSA §13702-A, sub-§4-A is enacted to read: 
4-A.  Compounding pharmacy.  "Compounding pharmacy" means a pharmacy that 
compounds drugs in compliance with the provisions of this chapter and the Federal Food, 
Drug, and Cosmetic Act.  "Compounding pharmacy" includes a nonsterile compounding 
pharmacy that meets the requirements for a compounding pharmacy and the requirements 
for a nonsterile compounding pharmacy as published in a nationally recognized 
compendium of drug substances, dosage forms and compounded preparations and a 
sterile compounding pharmacy that meets the requirements for a compounding pharmacy 
and the requirements for a sterile compounding pharmacy as published in a nationally 
recognized compendium of drug substances, dosage forms and compounded preparations. 
Sec. A-2.  32 MRSA §13712, as amended by PL 2007, c. 402, Pt. DD, §3, is 
further amended to read: 
§13712.  Membership 
The board consists of 7 members, two 2 of whom must be public members as defined 
in Title 5, section 12004-A and the remainder of whom must be licensed pharmacists who 
possess the qualifications specified in section 13713. At the time of the appointment, at 
least one of the licensed pharmacists must be a hospital pharmacist, at least one must be a 
chain pharmacist and at least one must be an independent pharmacist.  This paragraph is 
repealed January 1, 2014. 
Beginning with appointments made on or after January 1, 2014, the board consists of 
members, 2 of whom must be public members as defined in Title 5, section 12004-A, 
one of whom must be a physician licensed to practice under Title 32, chapter 36 or 48 
who has experience in public health, one of whom must be an advanced practice 
registered nurse approved to practice under Title 32, section 2205-B and the remainder of 
whom must be licensed pharmacists who possess the qualifications specified in section 
13713. At the time of the appointment, at least one of the licensed pharmacists must be a 
hospital pharmacist, at least one must be a chain pharmacist and at least one must be an 
independent pharmacist. 
Sec. A-3.  32 MRSA §13713, sub-§1, as enacted by PL 1987, c. 710, §5, is 
amended to read: 
1.  Public members. The public members of the board must be residents of this State 
who are at least 21 years of age and shall may not be, nor ever have been, members of the 
profession of pharmacy, the spouse of a member of the profession of pharmacy, a person 
who has ever had any material financial interest in providing pharmacy services or a 
person who has engaged in any activity directly related to the practice of pharmacy.  
Beginning with appointments made on or after January 1, 2014, one of the public 
members must be a person who has education and professional experience in the field of 
health care safety and quality assurance. 
Sec. A-4.  32 MRSA §13715-B is enacted to read: 
§13715-B.  Annual disclosure statement 
Each member of the board shall file a disclosure statement by December 31st each 
year that discloses any conflicts of interest of the member.  The board shall make 
available to the public on the board's website copies of the disclosure statements filed by 
board members.  The board shall adopt rules to implement this section.  Rules adopted 
pursuant to this section are routine technical rules as defined in Title 5, chapter 375, 
subchapter 2-A. 
Sec. A-5.  32 MRSA §13721, sub-§1, as amended by PL 2011, c. 496, §2, is 
further amended to read: 
1.  Responsibility. The board's responsibility for the control and regulation of the 
practice of pharmacy in this State includes, but is not limited to, the following actions: 
A.  The licensing by examination or by reciprocity of applicants who are qualified to 
engage in the practice of pharmacy under this Act; 
B.  The renewal of licenses to engage in the practice of pharmacy; 
C.  The determination and issuance of standards for recognition and approval of 
degree programs of schools and colleges of pharmacy whose graduates shall be 
eligible for licensure in this State and the specification and enforcement of 
requirements for practical training, including internship; 
D.  The inspection during business hours of all pharmacies, dispensaries, stores, 
hospital pharmacies, extended care facilities, boarding homes, nursing homes, drug 
abuse treatment centers, penal institutions, family planning centers or other drug 
outlets in which drugs or medicines are manufactured, stored, distributed, 
compounded, dispensed or retailed in this State; 
E.  The licensing of any pharmacy as set out in section 13751 and, any manufacturer 
or wholesaler whose products are distributed in this State and any pharmacy that 
compounds drugs that is licensed in another state and that compounds drugs that are 
delivered or dispensed in the State; 
F.    The enforcement of those provisions of this Act relating to the conduct or 
competence of pharmacists practicing in this State and the processing of complaints 
which could lead to the suspension, revocation or restriction of licenses to engage in 
the practice of pharmacy; 
G.  The licensing of pharmacy interns and adoption of rules governing the training, 
qualification and employment of pharmacy interns and pharmacy students; and 
H.    The licensing of pharmacy technicians, including the fee as set under section 
13724, and adoption of rules governing the training, qualification and employment of 
pharmacy technicians., including separate licensing categories for pharmacy 
technicians licensed for employment in sterile compounding pharmacies and in 
nonsterile compounding pharmacies; 
I.  Participation in a national data reporting system that provides information on 
individual pharmacies, pharmacists and pharmacy technicians; 
J.  The imposition of a fine for a violation of this chapter as provided in section 
13754, subsection 1; 
K.  Consultation with the Board of Licensure in Medicine on rules adopted pursuant 
to section 3269, subsection 18 for the compounding of drugs by physicians and 
consultation with the Board of Osteopathic Licensure on rules adopted pursuant to 
section 2581 for the compounding of drugs by osteopathic physicians; 
L.  The publication of a list, developed in cooperation with the Commissioner of 
Health and Human Services pursuant to Title 22, section 1834, of medications that 
may not be compounded by compounding pharmacies without prior approval of the 
board and a list of medications that may not be compounded by physicians without 
the approval of the Board of Licensure in Medicine or the Board of Osteopathic 
Licensure, as applicable to the physician.  In developing the lists of medications, the 
board and the Commissioner of Health and Human Services shall consider market 
availability of the medications, shortage of the medications, risk to patients and 
patient rights and cost; 
M.  Appointing and convening advisory committees to make recommendations to the 
board on licensure requirements under this chapter and qualifications for pharmacy 
personnel, compounding specifications and standards and continuing education 
standards; and 
N.  Making available to the public on the board's website information regarding all 
enforcement and disciplinary actions taken by the board related to pharmacies, 
pharmacists and pharmacy technicians in the State and information regarding 
pharmacy inspection results. Information made available to the public under this 
paragraph must be in a format that enables members of the public to search the 
information by name of pharmacy, pharmacist and pharmacy technician. 
Sec. A-6.  32 MRSA §13721, sub-§2, as amended by PL 1997, c. 245, §8, is 
further amended to read: 
2.  Reciprocal inspections.  The board may enter into reciprocal inspection 
agreements with any state in which a mail order prescription facility selling drugs to 
Maine citizens is located and any state in which a pharmacy is located that compounds 
drugs that are delivered or dispensed in the State. 
Sec. A-7.  32 MRSA §13722, sub-§1, ¶¶B and C, as enacted by PL 1987, c. 
710, §5, are amended to read: 
B.  Establish the specifications of minimum professional and technical equipment, 
environment, supplies and procedure for the compounding or dispensing of 
medications, drugs, devices and other materials within the practice of pharmacy.  
Specifications established under this paragraph must include specifications for sterile 
and nonsterile compounding pharmacies licensed in the State and for pharmacies that 
compound drugs that are delivered or dispensed in the State and that are licensed in 
another state; 
C.  Assure Ensure that standards for purity and quality of medications, drugs, devices 
and other materials within the practice of pharmacy are met.  Standards for purity and 
quality pursuant to this paragraph must include standards for sterile and nonsterile 
compounding pharmacies licensed in the State and for pharmacies that compound 
drugs that are delivered or dispensed in the State and that are licensed in another 
state; 
Sec. A-8.  32 MRSA §13722, sub-§1, ¶D, as amended by PL 2007, c. 402, Pt. 
DD, §9, is further amended to read: 
D.  Issue and renew licenses for purposes of ascertaining those persons engaged in 
the manufacture and distribution of drugs and for purposes of ascertaining those 
pharmacies that compound drugs that are delivered or dispensed in the State and that 
are licensed in another state; 
Sec. A-9.  32 MRSA §13723, sub-§7, as amended by PL 2009, c. 415, Pt. A, §19, 
is further amended to read: 
7.  Investigatory powers.  The board shall notify the Department of the Attorney 
General upon receipt of a complaint.  Upon receipt of the notifications, the Attorney 
General shall notify the department within a timely period if the alleged violation requires 
criminal investigation.  If a case does not require criminal investigation, the board or its 
authorized representatives may investigate and gather evidence concerning alleged 
violations of this Act or of the rules of the board. The board or an authorized 
representative pursuant to paragraph A may remove from any premises authorized for 
inspection pursuant to section 13721, subsection 1, paragraph D certain original records 
relating to scheduled drugs or controlled substances, including, but not limited to, 
prescription records, shipping and delivery records, patient profiles, inventories, all 
documentation related to the compounding of drugs and the delivery, distribution and 
dispensing of compounded drugs and other drug records for the purposes of analysis, 
duplication and furthering the investigation. A signed inventory receipt of any records 
being removed must be furnished to the premises by the board or an authorized 
representative.  When a means of producing legible photocopies is readily available at the 
site of the records being removed, an authorized representative removing the records shall 
leave photocopies of the records as part of an inventory receipt in accordance with this 
subsection.  Except when photocopies are left as part of an inventory receipt, the board or 
an authorized representative removing records from the premises shall, within 48 hours 
from the time of removal, provide to a representative of the premises photocopies of any 
removed records, together with a certificate identifying the agency in possession of the 
records, or return the original records.  Inventory receipts and photocopies of any 
removed records provided by the board or an authorized representative are admissible as 
evidence if offered by any representative of the premises to prove compliance with any 
rule of the board or requirement of law. 
A.  Prescriptions, orders and records required by this chapter and stocks of 
prescription and legend drugs are open only to the board, the board's authorized 
representatives, federal and state law enforcement officers whose duty it is to enforce 
the laws of this State or of the United States relating to scheduled drugs or controlled 
substances or to enforce conditions of probation or other supervision imposed by a 
court relating to scheduled drugs or controlled substances and other law enforcement 
officers authorized by the board, the Attorney General or the district attorney for the 
purposes of inspecting, investigating and gathering evidence of violations of law or 
any rule of the board.  A person having knowledge by virtue of the person's office of 
any such prescription, order or record may not divulge that knowledge, except before 
a licensing board or representative or in connection with a prosecution or proceeding 
in court. 
B.  The Bureau of Health Department of Health and Human Services, Maine Center 
for Disease Control and Prevention, the board, their officers, agents, inspectors and 
representatives, all peace officers within the State and all prosecuting attorneys shall 
enforce all provisions of this chapter, except those specifically delegated, and shall 
cooperate with all agencies charged with the enforcement of the laws of the United 
States, of this State and of all other states relating to prescription or legend drugs or 
their equivalent and to sterile and nonsterile compounding pharmacies licensed in the 
State and to sterile and nonsterile pharmacies that compound drugs that are delivered 
or dispensed in the State and that are licensed in another state. 
Sec. A-10.  32 MRSA §13724, as amended by PL 2007, c. 402, Pt. DD, §11 and 
PL 2011, c. 286, Pt. B, §5, is further amended to read: 
§13724.  Fees 
The Director of the Office of Professional and Occupational Regulation may establish 
by rule fees for purposes authorized under this chapter in amounts that are reasonable and 
necessary for their respective purposes, except that the fee for any one purpose may not 
exceed $325.  The fee schedule established under this section must establish different fees 
for pharmacies that do not compound drugs, pharmacies that are sterile compounding 
pharmacies and pharmacies that are nonsterile compounding pharmacies.  Rules adopted 
pursuant to this section are routine technical rules as defined in Title 5, chapter 375, 
subchapter 2-A.   
Sec. A-11.  32 MRSA §13735, 2nd ¶, as amended by PL 2009, c. 308, §2, is 
further amended to read: 
These courses consist of subject matter pertinent to the following general areas of 
professional pharmaceutical education: the socioeconomic and legal aspects of health 
care; the properties and actions of drugs and dosage forms; and the ideology, 
characteristics and therapeutics of the disease state. The specific subject matter of the 
courses may include, but is not limited to, pharmacology, biochemistry, physiology, 
pharmaceutical chemistry, sterile and nonsterile compounding of drugs, pharmacy 
administration, drug administration as it relates to the area of permitted practice, 
pharmacy jurisprudence, public health and communicable diseases, pharmaceutical 
marketing, professional practice management, anatomy, histology and such other subject 
matter as represented in curricula of accredited colleges of pharmacy. The content of each 
course offered for credit under this continuing professional educational program must be 
approved in advance of the course by the board or its representative. The board may make 
exceptions to this section in emergency or hardship cases. 
Sec. A-12.  32 MRSA §13751, sub-§2-A is enacted to read: 
2-A.  Compounding pharmacies.  In addition to a license in one of the 
classifications in subsection 2, a pharmacy that compounds drugs shall apply for a license 
as a compounding pharmacy and shall specify whether the pharmacy is a sterile 
compounding pharmacy or a nonsterile compounding pharmacy. 
Sec. A-13.  32 MRSA §13751, sub-§3, as amended by PL 2007, c. 402, Pt. DD, 
§23, is further amended to read: 
3.  Rules. The board shall establish by rule the criteria that each pharmacy must meet 
to qualify for licensure in each classification designated in subsection 2 and pursuant to 
subsection 2-A. The board may issue various types of licenses with varying restrictions to 
the pharmacies referred to in subsection 2, paragraph A when the board determines it 
necessary by reason of the type of pharmacy requesting a license. 
Sec. A-14.  32 MRSA §13751, sub-§5 is enacted to read: 
5.  Out-of-state pharmacies that compound drugs for delivery or dispensing in 
the State.  A pharmacy that is licensed in another state and that compounds drugs that are 
delivered or dispensed in this State shall annually obtain a license from the board under 
subsection 1 and shall comply with subsections 2 and 2-A and all other applicable 
provisions of this chapter. 
Sec. A-15.  32 MRSA §13752, sub-§2, as amended by PL 2007, c. 402, Pt. DD, 
§24, is further amended to read: 
2.  Required information. Applications for licenses must include the fee as set under 
section 13724 and the following information about the proposed pharmacy and 
pharmacist in charge: 
A.  Ownership of the pharmacy; 
B.  Location of the pharmacy; 
C.  Identity of the pharmacist licensed to practice in the State who will be the 
pharmacist in charge of the pharmacy, when one is required by this chapter, and such 
further information as the board may determine necessary. A pharmacist may be the 
pharmacist in charge for only one pharmacy, except upon the pharmacist applying for 
and receiving written authorization from the board. The position of pharmacist in 
charge may not be held by a qualified assistant pharmacist; and 
D.  A certification by the pharmacist identified as the pharmacist in charge that the 
pharmacist has read and understands the requirements and duties of a pharmacist in 
charge set forth in board rules.; and 
E.  Whether the pharmacy will operate as a sterile compounding pharmacy or a 
nonsterile compounding pharmacy or will not operate as a compounding pharmacy. 
Sec. A-16.  32 MRSA §13754, sub-§3 is enacted to read: 
3.  Out-of-state pharmacies.  A compounding pharmacy or a pharmacy that is 
licensed in another state that compounds drugs that are delivered or dispensed in the State 
shall comply with the requirements of this chapter. A pharmacy that violates this chapter 
commits a Class C crime for which a fine of not more than $25,000 may be adjudged. 
PART B 
Sec. B-1.  22 MRSA §§1833 to 1835 are enacted to read: 
§1833.  Compounding pharmacies in hospitals and nursing facilities 
The department, after consultation with the Maine Board of Pharmacy, shall adopt 
rules regarding compounding pharmacies in hospitals that compound drugs for use by 
patients of the hospital and compounding pharmacies in nursing facilities that compound 
drugs for use by patients of the nursing facility.  Rules adopted pursuant to this section 
apply in addition to any provisions of Title 32, chapter 117, subchapter 5 and are routine 
technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
§1834.  Limitation on authority to compound drugs 
The commissioner shall publish a list, developed in cooperation with the Maine 
Board of Pharmacy pursuant to Title 32, section 13721, subsection 1, paragraph L, of 
medications that may not be compounded by compounding pharmacies without prior 
approval of the board and a list of medications that may not be compounded by 
physicians without the approval of the Board of Licensure in Medicine or the Board of 
Osteopathic Licensure, as applicable to the physician.  In developing the lists of 
medications, the commissioner and the Maine Board of Pharmacy shall consider market 
availability of the medications, shortage of the medications, risk to patients, patient rights 
and cost. 
§1835.  Prohibited drug purchases 
A hospital, nursing facility or ambulatory surgical facility licensed under this chapter 
may not purchase drugs compounded by a pharmacy or other entity that is not licensed in 
the State.  A violation of this section is a violation of the terms of licensure of the 
hospital, nursing facility or ambulatory surgical center.  The department shall adopt rules 
to implement this section.  Rules adopted pursuant to this section are routine technical 
rules as defined in Title 5, chapter 375, subchapter 2-A. 
Sec. B-2.  22 MRSA §2149-B is enacted to read: 
§2149-B.  Prohibited drug purchases 
A home health care provider licensed under this chapter may not purchase drugs 
compounded by a pharmacy or other entity that is not licensed in the State.  A violation of 
this section is a violation of the terms of licensure of the home health care provider.  The 
department shall adopt rules to implement this section.  Rules adopted pursuant to this 
section are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
Sec. B-3.  22 MRSA §7808 is enacted to read: 
§7808.  Prohibited drug purchases 
A residential care facility, assisted housing program, drug treatment center or 
children's home licensed under this chapter may not purchase drugs compounded by a 
pharmacy or other entity that is not licensed in the State.  A violation of this section is a 
violation of the terms of licensure of the residential care facility, assisted housing 
program, drug treatment center or children's home. The department shall adopt rules to 
implement this section.  Rules adopted pursuant to this section are routine technical rules 
as defined in Title 5, chapter 375, subchapter 2-A. 
Sec. B-4.  22 MRSA §8624 is enacted to read: 
§8624.  Prohibited drug purchases 
A hospice program licensed under this chapter may not purchase drugs compounded 
by a pharmacy or other entity that is not licensed in the State.  A violation of this section 
is a violation of the terms of licensure of the hospice program.  The department shall 
adopt rules to implement this section.  Rules adopted pursuant to this section are routine 
technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
Sec. B-5.  22-A MRSA §206, sub-§9 is enacted to read: 
9.  Consultation services to the Maine Board of Pharmacy.  The commissioner, 
through the Director of the Maine Center for Disease Control and Prevention, shall 
provide consultation services to the Maine Board of Pharmacy on issues pertaining to 
epidemiology and public health. 
Sec. B-6.  32 MRSA §2108-B is enacted to read: 
§2108-B.  Prohibited drug purchases 
An individual licensed under this chapter may not purchase drugs compounded by a 
pharmacy or other entity that is not licensed in the State.  A violation of this section is a 
violation of the terms of licensure under this chapter.  The board shall adopt rules to 
implement this section.  Rules adopted pursuant to this section are routine technical rules 
as defined in Title 5, chapter 375, subchapter 2-A. 
Sec. B-7.  32 MRSA §2581, as amended by PL 2001, c. 492, §6, is further 
amended by adding at the end a new paragraph to read: 
An osteopathic physician licensed under this section may compound drugs in the 
physician's professional office for use by patients of the physician in accordance with 
rules adopted by the board under this section after consultation with the Maine Board of 
Pharmacy as provided in Title 32, section 13721, subsection 1, paragraph K. 
Sec. B-8.  32 MRSA §2600-C is enacted to read: 
§2600-C.  Prohibited drug purchases 
An osteopathic physician licensed under this chapter may not purchase drugs 
compounded by a pharmacy or other entity that is not licensed in the State.  A violation of 
this section is a violation of the terms of licensure of the osteopathic physician.  The 
board shall adopt rules to implement this section.  Rules adopted pursuant to this section 
are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
Sec. B-9.  32 MRSA §3269, sub-§16, as amended by PL 2001, c. 260, Pt. H, §2, 
is further amended to read: 
16.  Executive director.  The power to appoint an executive director who serves at 
the pleasure of the board and who shall assist the board in carrying out its administrative 
duties and responsibilities under this chapter.  The salary range for the executive director 
must be set by the board within the range established by Title 2, section 6-C; and 
Sec. B-10.  32 MRSA §3269, sub-§17, as enacted by PL 2001, c. 260, Pt. H, §3, 
is amended to read: 
17.  Approval of licenses.  The power to direct staff to review and approve 
applications for licensure or renewal in accordance with criteria established in law or in 
rules adopted by the board.  Licensing decisions made by staff may be appealed to the 
full board.; and 
Sec. B-11.  32 MRSA §3269, sub-§18 is enacted to read: 
18.  Compounding of drugs.  The power to adopt rules that grant to a physician or 
surgeon licensed under this chapter authorization to compound drugs in the physician's or 
surgeon's professional office for use by patients of the physician or surgeon after 
consultation with the Maine Board of Pharmacy as provided in Title 32, section 13721, 
subsection 1, paragraph K.  Rules adopted pursuant to this subsection are routine 
technical rules as defined in Title 5, chapter 375, subchapter 2-A. 
Sec. B-12.  32 MRSA §3300-D is enacted to read: 
§3300-D.  Prohibited drug purchases 
A physician licensed under this chapter may not purchase drugs compounded by a 
pharmacy or other entity that is not licensed in the State.  A violation of this section is a 
violation of the terms of licensure of the physician.  The board shall adopt rules to 
implement this section.  Rules adopted pursuant to this section are routine technical rules 
as defined in Title 5, chapter 375, subchapter 2-A. 
SUMMARY 
This bill strengthens Maine's laws on compounding pharmacies.  The bill contains the 
following provisions. 
1.  The bill provides a definition for "compounding pharmacy" and describes sterile 
compounding pharmacies and nonsterile compounding pharmacies. 
2.  Beginning with appointments made on or after January 1, 2014, the bill adds a 
physician and an advanced practice registered nurse to the Maine Board of Pharmacy, 
decreases the number of pharmacist members from 5 to 3 and requires that one public 
member be a person who has education and professional experience in the field of health 
care safety and quality assurance.  The bill requires members of the Maine Board of 
Pharmacy to file by December 31st an annual statement disclosing any conflicts of 
interest and requires the Maine Board of Pharmacy to post the statements on the board's 
publicly accessible website. 
3.  The bill requires licensed pharmacies that are compounding pharmacies to obtain 
a license as a compounding pharmacy and to specify whether the pharmacy is a nonsterile 
compounding pharmacy or a sterile compounding pharmacy.  The bill requires the Maine 
Board of Pharmacy to adopt rules to establish the criteria for licensure as a compounding 
pharmacy. 
4.  The bill extends the responsibility of the Maine Board of Pharmacy to include 
licensing out-of-state compounding pharmacies that are licensed in another state and that 
deliver or dispense drugs in the State.  The bill grants to the Maine Board of Pharmacy 
the authority to appoint and convene advisory committees and the responsibility to 
impose a fine on a compounding pharmacy that violates the Maine Pharmacy Act.  The 
bill requires the Maine Board of Pharmacy to participate in a national data reporting 
system on pharmacies, pharmacists and pharmacy technicians.  The bill requires the 
Maine Board of Pharmacy to license pharmacy technicians in 2 categories: those that are 
licensed for employment in sterile compounding pharmacies and those that are licensed 
for employment in nonsterile compounding pharmacies.  The bill requires the Maine 
Board of Pharmacy to make available to the public on its website, in a searchable format, 
information regarding disciplinary and enforcement actions taken by the board and the 
results of pharmacy inspections. 
5.  The bill further extends the responsibility of the Maine Board of Pharmacy to 
allow consultation with the Board of Licensure in Medicine, the Board of Osteopathic 
Licensure and the Commissioner of Health and Human Services regarding the 
compounding of drugs. 
6.  The bill requires the Maine Board of Pharmacy to ensure standards for purity and 
quality are met by compounding pharmacies. 
7.  With regard to the investigatory powers of the Maine Board of Pharmacy, the bill 
adds documentation regarding compounding to the list of items that the board may 
remove from a premises being inspected. 
8.  The bill requires the Department of Health and Human Services, Maine Center for 
Disease Control and Prevention and the Maine Board of Pharmacy and law enforcement 
to cooperate with other law enforcement agencies concerned with compounding 
pharmacies. 
9.  The bill requires that licensing fees for pharmacies distinguish those that are not 
compounding pharmacies from those that are compounding pharmacies and, among 
compounding pharmacies, distinguish nonsterile compounding pharmacies from sterile 
compounding pharmacies. 
10.  The bill adds sterile and nonsterile compounding of drugs to the specific subject 
matter of course work for continuing education for pharmacists. 
11.  The bill makes a violation of the Maine Pharmacy Act by a compounding 
pharmacy a Class C crime and authorizes a fine of up to $25,000. 
12.  The bill requires the Department of Health and Human Services to adopt rules 
regarding compounding pharmacies in hospitals and nursing facilities. 
13.  The bill requires the Commissioner of Health and Human Services, through the 
Director of the Maine Center for Disease Control and Prevention, to provide consultation 
services to the Maine Board of Pharmacy on issues related to epidemiology and public 
health. 
14.  The bill prohibits licensed health care facilities and practitioners from purchasing 
drugs compounded by a pharmacy or other entity that is not licensed in Maine, designates 
such purchases a violation of the licensure statutes and directs the licensing authorities to 
adopt rules to enforce the prohibition.